| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | Director
2 companies
Shah Jaisim is a See Remarks at SCLX, with reported holdings spanning 2 companies. Recent filings cover 8 purchases and 0 sales. Those positions are worth an estimated $266K at current prices.
Our model assigns Shah Jaisim a below-average insider score of 25/100, based on 5 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -57.1%.
Shah Jaisim's largest disclosed position is in SRNE as Director, worth about $202K. Net of sales, the recent Form 4 record there shows accumulation of 47,191 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | SCLX Scilex Holding Co | See Remarks | Buy | 30,000 | $0.46 | $13,800.00 | +27.4% | -32.7% | -9.1% | |
| Oct 29, 2024 | SCLX Scilex Holding Co | See Remarks | Buy | 32,000 | $0.99 | $31,670.40 | +41.4% | -53.8% | -47.0% | |
| Oct 16, 2024 | SCLX Scilex Holding Co | See Remarks | Buy | 30,000 | $0.99 | $29,751.00 | +63.4% | -48.3% | -56.3% | |
| May 17, 2024 | SCLX Scilex Holding Co | See Remarks | Buy | 140,000 | $0.87 | $121,945.18 | +881.5% | +37.8% | -86.6% | |
| Jun 15, 2017 | SRNE Sorrento Therapeutics, Inc. | Director | Buy | 10,002 | $1.79 | $17,903.58 | +9.7% | - | - | |
| Feb 3, 2017 | SRNE Sorrento Therapeutics, Inc. | Director | Buy | 10,000 | $5.15 | $51,500.00 | +10.8% | - | - | |
| Aug 3, 2015 | SRNE Sorrento Therapeutics, Inc. | Director | Buy | 27,189 | $11.50 | $312,673.50 | +41.5% | - | - |